Journal article · 2026 · Open access
Single Intranasal Administration of the Psychedelic Mebufotenin for Treatment-Resistant Depression: A Randomized Clinical Trial
JAMA · Published 26 October 2026 · DOI 10.1001/jama.2026.18380
In brief
“Single Intranasal Administration of the Psychedelic Mebufotenin for Treatment-Resistant Depression: A Randomized Clinical Trial” is a 2026 journal article by David Feifel and 14 co-authors, published in JAMA. OpenAlex counts 1 citations as of 17 November 2026, which puts it in the top 9% of works published in 2026 by citations. It is open access: the full text is free to read at PubMed Central.
- Citations
- 1
- Most cited in
- 2026 (1)
- Field-weighted impact
- 4.88
- References
- 43
- Authors
- 15
Abstract
Importance: Psychedelics represent a potential breakthrough for treatment-resistant depression; however, the prolonged in-clinic monitoring required for compounds such as psilocybin and lysergic acid diethylamide is a logistical hurdle to widespread use. Intranasal mebufotenin (5-methoxy-N,N-dimethyltryptamine), a 5-hydroxytryptamine 1A (5-HT1A) and 5-HT2A agonist associated with brief psychedelic experiences, may address this limitation. Objective: To evaluate the safety, efficacy, and time to discharge readiness following a single dose of intranasal mebufotenin benzoate in adults with treatment-resistant depression. Design, Setting, and Participants: Phase 2b, randomized, double-blind trial with an 8-week blinded follow-up conducted between September 2023 and April 2025 at 38 sites in Australia, Europe, and the US. Participants were aged 18 to 75 years with moderate to severe major depressive disorder nonresponsive to 2 to 5 antidepressant trials in the current episode. The last date of follow-up was April 28, 2025. Interventions: After antidepressant washout as needed, participants were randomly assigned to receive a single dose of intranasal mebufotenin benzoate, 8 mg (n = 46), 12 mg (n = 73), or 0.3 mg (a low-dose comparator; n = 74), alongside psychological support. Main Outcomes and Measures: The primary end point was total score change on the Montgomery-Åsberg Depression Rating Scale (MADRS; score range, 0-60; higher scores indicate more severe depression) from baseline to day 29 in the 12-mg vs 0.3-mg dose groups. Eighteen secondary end points were assessed for the 12-mg and 8-mg vs 0.3-mg doses. Discharge readiness was assessed starting 90 minutes after dosing. Results: Among the 193 included participants, the mean age was 41 (SD, 11.1) years and 59.1% were female. From baseline to day 29, treatment with 12-mg intranasal mebufotenin benzoate vs the 0.3-mg dose (the primary end point) was associated with significantly reduced MADRS scores (mean score change, -11.1 [SD, 11.6] vs -5.5 [SD, 9.9], respectively; mean difference, -5.3 [95% CI, -8.9 to -1.8]; P = .003). The 8-mg dose also led to reduced scores from baseline to day 29 (mean score change, -12.5 [SD, 12.7]) vs the 0.3-mg dose (mean difference, -6.2 [95% CI, -10.2 to -2.1]; P = .003). MADRS reductions with the 8-mg and 12-mg doses were similar and significantly greater at all other time points from 2 to 57 days post dose vs the 0.3-mg dose. Day 29 response rates were 35%, 34%, and 12% and remission rates were 26%, 18%, and 8% in the 8-mg, 12-mg, and 0.3-mg dose groups, respectively. Treatment-emergent adverse events were reported in 76%, 85%, and 73% of participants in the 8-mg, 12-mg, and 0.3-mg dose groups, respectively; most events…
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Feifel, D., Seynaeve, M., Cubała, W. J., Dunbar, F., Gründer, G., Herrero, R. M. D., Hindocha, C., Liknaitzky, P., Mcguigan, S., Mehta, S., Pierce, M., Repantis, D., Roberts, C., Wiegand, F., & Conley, R. R. (2026). Single Intranasal Administration of the Psychedelic Mebufotenin for Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA. https://doi.org/10.1001/jama.2026.18380
MLA 9
Feifel, David, et al. “Single Intranasal Administration of the Psychedelic Mebufotenin for Treatment-Resistant Depression: A Randomized Clinical Trial.” JAMA, 2026. https://doi.org/10.1001/jama.2026.18380.
Chicago
Feifel, David, Mathieu Seynaeve, Wiesław Jerzy Cubała, Fiona Dunbar, Gerhard Gründer, Rosa María Dueñas Herrero, Chandni Hindocha, et al. 2026. “Single Intranasal Administration of the Psychedelic Mebufotenin for Treatment-Resistant Depression: A Randomized Clinical Trial.” JAMA. https://doi.org/10.1001/jama.2026.18380.
Harvard
Feifel, D. et al. (2026) ‘Single Intranasal Administration of the Psychedelic Mebufotenin for Treatment-Resistant Depression: A Randomized Clinical Trial’, JAMA. doi:10.1001/jama.2026.18380.
IEEE
D. Feifel et al., “Single Intranasal Administration of the Psychedelic Mebufotenin for Treatment-Resistant Depression: A Randomized Clinical Trial,” JAMA, 2026, doi: 10.1001/jama.2026.18380.
BibTeX
@article{feifel2026single,
title = {{Single Intranasal Administration of the Psychedelic Mebufotenin for Treatment-Resistant Depression: A Randomized Clinical Trial}},
author = {Feifel, David and Seynaeve, Mathieu and Cubała, Wiesław Jerzy and Dunbar, Fiona and Gründer, Gerhard and Herrero, Rosa María Dueñas and Hindocha, Chandni and Liknaitzky, Paul and Mcguigan, Sean and Mehta, Sejal and Pierce, Mimi and Repantis, Dimitris and Roberts, Claire and Wiegand, Frank and Conley, Robert R.},
journal = {JAMA},
year = {2026},
doi = {10.1001/jama.2026.18380},
url = {https://doi.org/10.1001/jama.2026.18380}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- 5-MeO-DMT
- treatment-resistant depression
- major depressive disorder
- intranasal administration
- psychedelic therapy
- discharge readiness
- adverse events
- dose comparison
Work with this paper
Most-cited papers in Psychology
- Diagnostic and Statistical Manual of Mental DisordersAndrés Santiago González Moreno · American Psychiatric Association Publishing eBooks · 2013 · 123,932 citations
- The theory of planned behaviorIcek Ajzen · Organizational Behavior and Human Decision Processes · 1991 · 106,482 citations
- Self-efficacy: Toward a unifying theory of behavioral change.Albert Bandura · Psychological Review · 1977 · 61,923 citations
- Self-determination theory and the facilitation of intrinsic motivation, social development, and well-being.Richard M. Ryan, Edward L. Deci · American Psychologist · 2000 · 55,457 citations
- Mind in Society: The Development of Higher Psychological ProcessesL. S. Vygotsky · 기초학문자료센터(KRM) (Korea Research Foundation) · 1978 · 53,340 citations
Questions about this paper
How do I cite this paper in APA style?
Feifel, D., Seynaeve, M., Cubała, W. J., Dunbar, F., Gründer, G., Herrero, R. M. D., Hindocha, C., Liknaitzky, P., Mcguigan, S., Mehta, S., Pierce, M., Repantis, D., Roberts, C., Wiegand, F., & Conley, R. R. (2026). Single Intranasal Administration of the Psychedelic Mebufotenin for Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA. https://doi.org/10.1001/jama.2026.18380
How many times has this paper been cited?
1 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at PubMed Central: sign in and open the full text from this page.
Who wrote this paper?
David Feifel, Mathieu Seynaeve, Wiesław Jerzy Cubała, Fiona Dunbar, Gerhard Gründer, Rosa María Dueñas Herrero, Chandni Hindocha, Paul Liknaitzky, Sean Mcguigan, Sejal Mehta, Mimi Pierce, Dimitris Repantis and 3 more.
What is the DOI of this paper?
10.1001/jama.2026.18380, permanently at https://doi.org/10.1001/jama.2026.18380. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.